Your browser doesn't support javascript.
loading
NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?
Ametovski, Adam; Cairns, Elizabeth A; Grafinger, Katharina Elisabeth; Cannaert, Annelies; Deventer, Marie H; Chen, Shuli; Wu, Xinyi; Shepperson, Caitlin E; Lai, Felcia; Ellison, Ross; Gerona, Roy; Blakey, Karen; Kevin, Richard; McGregor, Iain S; Hibbs, David E; Glass, Michelle; Stove, Christophe; Auwärter, Volker; Banister, Samuel D.
Afiliação
  • Ametovski A; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
  • Cairns EA; School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
  • Grafinger KE; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
  • Cannaert A; School of Psychology, The University of Sydney, Sydney, NSW 2006, Australia.
  • Deventer MH; Institute of Forensic Medicine, Forensic Toxicology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
  • Chen S; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
  • Wu X; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
  • Shepperson CE; Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
  • Lai F; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
  • Ellison R; School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
  • Gerona R; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
  • Blakey K; School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
  • Kevin R; Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales 2050, Australia.
  • McGregor IS; Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, California 94143, United States.
  • Hibbs DE; Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, California 94143, United States.
  • Glass M; Illicit Drug Group, Forensic Chemistry, QHFSS, Queensland Health, Coopers Plains, Brisbane, QLD 4108, Australia.
  • Stove C; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
  • Auwärter V; School of Psychology, The University of Sydney, Sydney, NSW 2006, Australia.
  • Banister SD; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
ACS Chem Neurosci ; 12(21): 4020-4036, 2021 11 03.
Article em En | MEDLINE | ID: mdl-34676751
ABSTRACT
Synthetic cannabinoid receptor agonists (SCRAs) remain a prolific class of new psychoactive substances (NPS) and continue to expand rapidly. Despite the recent identification of hydroxybenzotriazole (HOBt) containing SCRAs in synthetic cannabis samples, there is currently no information regarding the pharmacological profile of these NPS with respect to human CB1 and CB2 receptors. In the current study, a series consisting of seven HOBt indole-, indazole-, and 7-azaindole-carboxylates bearing a range of N-alkyl substituents were synthesized and pharmacologically evaluated. Competitive binding assays at CB1 and CB2 demonstrated that all analogues except a 2-methyl-substituted derivative had low affinity for CB1 (Ki = 3.80-43.7 µM) and CB2 (Ki = 2.75-18.2 µM). A fluorometric functional assay revealed that 2-methylindole- and indole-derived HOBt carboxylates were potent and efficacious agonists of CB1 (EC50 = 12.0 and 63.7 nM; Emax = 118 and 120%) and CB2 (EC50 = 10.9 and 321 nM; Emax = 91 and 126%). All other analogues incorporating indazole and 7-azaindole cores and bearing a range of N1-substituents showed relatively low potency for CB1 and CB2. Additionally, a reporter assay monitoring ß-arrestin 2 (ßarr2) recruitment to the receptor revealed that the 2-methylindole example was the most potent and efficacious at CB1 (EC50 = 131 nM; Emax = 724%) and the most potent at CB2 (EC50 = 38.2 nM; Emax = 51%). As with the membrane potential assay, the indazole and other indole HOBt carboxylates were considerably less potent at both receptors, and analogues comprising a 7-azaindole core showed little activity. Taken together, these data suggest that NNL-3 demonstrates little CB1 receptor activity and is unlikely to be psychoactive in humans. NNL-3 is likely an unintended SCRA manufacturing byproduct. However, the synthesis of NNL-3 analogues proved simple and general, and some of these showed potent cannabimetic profiles in vitro, indicating that HOBt esters of this type may represent an emerging class of SCRA NPS.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ésteres / Agonistas de Receptores de Canabinoides Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ésteres / Agonistas de Receptores de Canabinoides Idioma: En Ano de publicação: 2021 Tipo de documento: Article